Neonatal carnitine palmitoyltransferase II deficiency: failure of treatment despite prolonged survival
- Petra Hissink-Muller1,
- Enrico Lopriore2,
- Carolien Boelen1,
- Frans Klumper3,
- Marinus Duran4,
- Frans Walther1
- 1Leiden University Medical Center, Pediatrics, Albinusdreef 2, Leiden, The Netherlands
- 2Leiden University Medical Center, Albinusdreef 2, Leiden, 9600 rc, The Netherlands
- 3Leiden University Medical Center, Obstetrics and Gynecology, Albinusdreef 2, Leiden, The Netherlands
- 4Academic Medical Center Amsterdam, Laboratory of Genetic and Metabolic Diseases, Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands
- Enrico Lopriore, e.lopriore{at}lumc.nl
- Published 26 June 2009
Summary
Carnitine palmitoyltransferase (CPT) deficiencies are disorders of mitochondrial fatty acid oxidation (FAO). In fatty acid oxidation, long-chain fatty acids need the carnitine cycle to be transported from the cytosol to the mitochondria. In CPT II deficiency, long-chain acylcarnitines cannot be metabolised to carnitine and acyl-CoA, leading to accumulation of toxic long-chain acylcarnitines. Three clinical presentations of CPT II deficiency have been identified: the adult form, the infantile form and the neonatal form. The neonatal form of CPT II is the most severe and all reported patients died within a few days to 6 weeks after birth. The first case of a patient with neonatal CPT II deficiency surviving beyond the neonatal period is described. Unfortunately, the infant died at the age of 6 months due to untreatable cardiac arrhythmias.
Footnotes
-
Competing interests: None.
-
Patient consent: Patient/guardian consent was obtained for publication.








